KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 108 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 4.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $28,453,000 | +11.4% | 1,930,322 | 0.0% | 0.62% | +38.0% |
Q4 2021 | $25,538,000 | -24.2% | 1,930,322 | 0.0% | 0.45% | -3.6% |
Q3 2021 | $33,684,000 | -27.2% | 1,930,322 | 0.0% | 0.47% | -37.1% |
Q2 2021 | $46,251,000 | +414.4% | 1,930,322 | +451.5% | 0.74% | +445.6% |
Q1 2021 | $8,992,000 | -78.2% | 350,000 | -75.7% | 0.14% | -92.4% |
Q1 2019 | $41,243,000 | +44.9% | 1,441,070 | 0.0% | 1.78% | +7.3% |
Q4 2018 | $28,461,000 | -10.7% | 1,441,070 | 0.0% | 1.66% | -2.7% |
Q3 2018 | $31,862,000 | +172.3% | 1,441,070 | 0.0% | 1.70% | +124.1% |
Q2 2018 | $11,701,000 | -14.3% | 1,441,070 | 0.0% | 0.76% | -27.4% |
Q1 2018 | $13,661,000 | -2.8% | 1,441,070 | 0.0% | 1.05% | -11.0% |
Q4 2017 | $14,050,000 | +223.0% | 1,441,070 | +143.8% | 1.18% | +199.2% |
Q3 2017 | $4,350,000 | 0.0% | 591,070 | 0.0% | 0.39% | -21.2% |
Q2 2017 | $4,350,000 | -5.8% | 591,070 | 0.0% | 0.50% | -11.8% |
Q1 2017 | $4,616,000 | +10.5% | 591,070 | 0.0% | 0.57% | -4.4% |
Q4 2016 | $4,179,000 | – | 591,070 | – | 0.59% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |